IMU Biosciences is a biotechnology company based in London that combines systems-level immune profiling with artificial intelligence for precision medicine. Its HD Immunology platform pairs massively scalable immune phenotyping with proprietary real-time AI analytics. From 2ml of blood it measures over 100 million immune data points and resolves 2,500 discrete immune cell subsets in real time, producing immune insights intended for use at clinical scale.
The technology rests on a multi-omic approach to immune measurement and is backed by what the company describes as the world's largest immune dataset: more than 25,000 deeply characterised samples spanning health and disease. IMU's stated ambition is to become the universal standard for immune measurement.
The work is grounded in decades of research at King's College London and the Francis Crick Institute. Application areas include immuno-oncology, haematopoietic stem cell transplantation, solid organ transplantation and immune-mediated diseases. IMU partners with leading pharmaceutical and biotechnology companies on biomarker and immune measurement programmes.
